Novabay Pharmaceuticals Inc Market cap
What is the Market cap of Novabay Pharmaceuticals Inc?
The Market cap of Novabay Pharmaceuticals Inc is $3.25M
What is the definition of Market cap?
Market capitalization is the market value at a point in time of the shares outstanding of a publicly traded company, being equal to the share price at that point of time times the number of shares outstanding.
= outstanding shares * previous day’s close
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Market cap of companies in the Health Care sector on NYSEMKT compared to Novabay Pharmaceuticals Inc
What does Novabay Pharmaceuticals Inc do?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Companies with market cap similar to Novabay Pharmaceuticals Inc
- Solis Minerals Ltd has Market cap of $3.23M
- Nugen Medical Devices Inc has Market cap of $3.23M
- Super Crop Safe has Market cap of $3.23M
- R&R Real Estate Investment Trust has Market cap of $3.23M
- Champion Bear Resources has Market cap of $3.24M
- Myanmar Investments International has Market cap of $3.24M
- Novabay Pharmaceuticals Inc has Market cap of $3.25M
- BlueRush has Market cap of $3.25M
- Lions Bay Capital has Market cap of $3.25M
- BikeExchange Pty Ltd has Market cap of $3.25M
- Schmitt Industries Inc has Market cap of $3.25M
- Getty Copper has Market cap of $3.25M
- Acura Pharmaceuticals has Market cap of $3.25M